Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era

The ongoing coronavirus (COVID-19) pandemic is a global health emergency of international concern and has affected management plans of many autoimmune disorders. Immunosuppressive and immunomodulatory therapies are pivotal in the management of neuromyelitis optica spectrum disorder (NMOSD), potentia...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutics and clinical risk management 2020-01, Vol.16, p.759-767
Main Authors: Hamdy, Sherif M, Abdel-Naseer, Maged, Shehata, Hatem S, Shalaby, Nevin M, Hassan, Amr, Elmazny, Alaa, Shaker, Ehab, Nada, Mona A F, Ahmed, Sandra M, Hegazy, Mohamed I, Mourad, Husam S, Abdelalim, Ahmed, Magdy, Rehab, Othman, Alshimaa S, Mekkawy, Doaa A, Kishk, Nirmeen A
Format: Article
Language:English
Subjects:
Antibodies
Blood tests
Coronaviruses
COVID-19
covid19
Cytokines
Drug dosages
Immunoglobulins
Infections
Laboratories
Lymphocytes
neuromyelitis optica spectrum disorder
pandemic
Pandemics
Pathophysiology
Patients
Review
Severe acute respiratory syndrome coronavirus 2
Tumor necrosis factor-TNF
Viral infections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c478t-5c2679271a44b38783220907f4032e27c0d4b95b892d1f8c709dc3a70e2e08bf3
cites cdi_FETCH-LOGICAL-c478t-5c2679271a44b38783220907f4032e27c0d4b95b892d1f8c709dc3a70e2e08bf3
container_end_page 767
container_issue
container_start_page 759
container_title Therapeutics and clinical risk management
container_volume 16
creator Hamdy, Sherif M
Abdel-Naseer, Maged
Shehata, Hatem S
Shalaby, Nevin M
Hassan, Amr
Elmazny, Alaa
Shaker, Ehab
Nada, Mona A F
Ahmed, Sandra M
Hegazy, Mohamed I
Mourad, Husam S
Abdelalim, Ahmed
Magdy, Rehab
Othman, Alshimaa S
Mekkawy, Doaa A
Kishk, Nirmeen A
description The ongoing coronavirus (COVID-19) pandemic is a global health emergency of international concern and has affected management plans of many autoimmune disorders. Immunosuppressive and immunomodulatory therapies are pivotal in the management of neuromyelitis optica spectrum disorder (NMOSD), potentially placing patients at an increased risk of contracting infections such as COVID-19. The optimal management strategy of NMOSD during the COVID-19 era remains unclear. Here, however, we examined the evidence of NMOSD disease-modifying therapies (DMTs) use during the present period and highlighted different scenarios including treatment of relapses as well as initiation and maintenance of DMTs in order to optimize care of NMOSD patients in the COVID-19 era.
doi_str_mv 10.2147/TCRM.S261753
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_ad38ef8327af490999c8faf9b1b17516</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_ad38ef8327af490999c8faf9b1b17516</doaj_id><sourcerecordid>2434575807</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-5c2679271a44b38783220907f4032e27c0d4b95b892d1f8c709dc3a70e2e08bf3</originalsourceid><addsrcrecordid>eNpdks9v0zAUxyMEYmNw44wsceFAhn8lti9IUzug0kYRHYib5TgvraskLrYD2n-P15aJcbL1_NHHfs_fonhJ8DklXLy7mX29Pl_RmoiKPSpOCRGypJj9eLzf12XNWH1SPItxizGvlSJPixNGpeRUiNNivDajWcMAY0KrFEyCtYOIfIe-mORyNaLfLm3QZ5iCH26hd8lFtNwlZw1a7cCmMA1o7qIPLQQ0n4Ib1yhtAM2W3xfzkqgsGlsYnEWXwTwvnnSmj_DiuJ4V3z5c3sw-lVfLj4vZxVVpuZCprCythaKCGM4bJoVklGKFRccxo0CFxS1vVNVIRVvSSSuwai0zAgMFLJuOnRWLg7f1Zqt3wQ0m3GpvnN4XfFhrE3IPPWjTMgldvkGYjiuslLKyM51qSJNHSursen9w7aZmgNbmoQTTP5A-PBndRq_9Ly04ZxiLLHhzFAT_c4KY9OCihb43I_gpasp5_hnOqczo6__QrZ_CmEeVKcYrUcm98O2BssHHGKC7fwzB-i4U-i4U-hiKjL_6t4F7-G8K2B96xLGt</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2434575807</pqid></control><display><type>article</type><title>Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era</title><source>PubMed Central Free</source><source>DOVE Medical Press Journals</source><source>Publicly Available Content Database</source><source>Taylor &amp; Francis Open Access Journals</source><source>Coronavirus Research Database</source><creator>Hamdy, Sherif M ; Abdel-Naseer, Maged ; Shehata, Hatem S ; Shalaby, Nevin M ; Hassan, Amr ; Elmazny, Alaa ; Shaker, Ehab ; Nada, Mona A F ; Ahmed, Sandra M ; Hegazy, Mohamed I ; Mourad, Husam S ; Abdelalim, Ahmed ; Magdy, Rehab ; Othman, Alshimaa S ; Mekkawy, Doaa A ; Kishk, Nirmeen A</creator><creatorcontrib>Hamdy, Sherif M ; Abdel-Naseer, Maged ; Shehata, Hatem S ; Shalaby, Nevin M ; Hassan, Amr ; Elmazny, Alaa ; Shaker, Ehab ; Nada, Mona A F ; Ahmed, Sandra M ; Hegazy, Mohamed I ; Mourad, Husam S ; Abdelalim, Ahmed ; Magdy, Rehab ; Othman, Alshimaa S ; Mekkawy, Doaa A ; Kishk, Nirmeen A</creatorcontrib><description>The ongoing coronavirus (COVID-19) pandemic is a global health emergency of international concern and has affected management plans of many autoimmune disorders. Immunosuppressive and immunomodulatory therapies are pivotal in the management of neuromyelitis optica spectrum disorder (NMOSD), potentially placing patients at an increased risk of contracting infections such as COVID-19. The optimal management strategy of NMOSD during the COVID-19 era remains unclear. Here, however, we examined the evidence of NMOSD disease-modifying therapies (DMTs) use during the present period and highlighted different scenarios including treatment of relapses as well as initiation and maintenance of DMTs in order to optimize care of NMOSD patients in the COVID-19 era.</description><identifier>ISSN: 1176-6336</identifier><identifier>ISSN: 1178-203X</identifier><identifier>EISSN: 1178-203X</identifier><identifier>DOI: 10.2147/TCRM.S261753</identifier><identifier>PMID: 32884277</identifier><language>eng</language><publisher>New Zealand: Taylor &amp; Francis Ltd</publisher><subject>Antibodies ; Blood tests ; Coronaviruses ; COVID-19 ; covid19 ; Cytokines ; Drug dosages ; Immunoglobulins ; Infections ; Laboratories ; Lymphocytes ; neuromyelitis optica spectrum disorder ; pandemic ; Pandemics ; Pathophysiology ; Patients ; Review ; Severe acute respiratory syndrome coronavirus 2 ; Tumor necrosis factor-TNF ; Viral infections</subject><ispartof>Therapeutics and clinical risk management, 2020-01, Vol.16, p.759-767</ispartof><rights>2020 Hamdy et al.</rights><rights>2020. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Hamdy et al. 2020 Hamdy et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-5c2679271a44b38783220907f4032e27c0d4b95b892d1f8c709dc3a70e2e08bf3</citedby><cites>FETCH-LOGICAL-c478t-5c2679271a44b38783220907f4032e27c0d4b95b892d1f8c709dc3a70e2e08bf3</cites><orcidid>0000-0003-4410-7814 ; 0000-0002-3556-3749 ; 0000-0001-6445-5539 ; 0000-0002-4865-1457 ; 0000-0003-0976-9011 ; 0000-0001-5012-3998 ; 0000-0002-2053-980X ; 0000-0002-8969-8825 ; 0000-0002-1994-3186 ; 0000-0001-7374-7074</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2434575807/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2434575807?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3862,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793,74412,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32884277$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hamdy, Sherif M</creatorcontrib><creatorcontrib>Abdel-Naseer, Maged</creatorcontrib><creatorcontrib>Shehata, Hatem S</creatorcontrib><creatorcontrib>Shalaby, Nevin M</creatorcontrib><creatorcontrib>Hassan, Amr</creatorcontrib><creatorcontrib>Elmazny, Alaa</creatorcontrib><creatorcontrib>Shaker, Ehab</creatorcontrib><creatorcontrib>Nada, Mona A F</creatorcontrib><creatorcontrib>Ahmed, Sandra M</creatorcontrib><creatorcontrib>Hegazy, Mohamed I</creatorcontrib><creatorcontrib>Mourad, Husam S</creatorcontrib><creatorcontrib>Abdelalim, Ahmed</creatorcontrib><creatorcontrib>Magdy, Rehab</creatorcontrib><creatorcontrib>Othman, Alshimaa S</creatorcontrib><creatorcontrib>Mekkawy, Doaa A</creatorcontrib><creatorcontrib>Kishk, Nirmeen A</creatorcontrib><title>Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era</title><title>Therapeutics and clinical risk management</title><addtitle>Ther Clin Risk Manag</addtitle><description>The ongoing coronavirus (COVID-19) pandemic is a global health emergency of international concern and has affected management plans of many autoimmune disorders. Immunosuppressive and immunomodulatory therapies are pivotal in the management of neuromyelitis optica spectrum disorder (NMOSD), potentially placing patients at an increased risk of contracting infections such as COVID-19. The optimal management strategy of NMOSD during the COVID-19 era remains unclear. Here, however, we examined the evidence of NMOSD disease-modifying therapies (DMTs) use during the present period and highlighted different scenarios including treatment of relapses as well as initiation and maintenance of DMTs in order to optimize care of NMOSD patients in the COVID-19 era.</description><subject>Antibodies</subject><subject>Blood tests</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>covid19</subject><subject>Cytokines</subject><subject>Drug dosages</subject><subject>Immunoglobulins</subject><subject>Infections</subject><subject>Laboratories</subject><subject>Lymphocytes</subject><subject>neuromyelitis optica spectrum disorder</subject><subject>pandemic</subject><subject>Pandemics</subject><subject>Pathophysiology</subject><subject>Patients</subject><subject>Review</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Tumor necrosis factor-TNF</subject><subject>Viral infections</subject><issn>1176-6336</issn><issn>1178-203X</issn><issn>1178-203X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdks9v0zAUxyMEYmNw44wsceFAhn8lti9IUzug0kYRHYib5TgvraskLrYD2n-P15aJcbL1_NHHfs_fonhJ8DklXLy7mX29Pl_RmoiKPSpOCRGypJj9eLzf12XNWH1SPItxizGvlSJPixNGpeRUiNNivDajWcMAY0KrFEyCtYOIfIe-mORyNaLfLm3QZ5iCH26hd8lFtNwlZw1a7cCmMA1o7qIPLQQ0n4Ib1yhtAM2W3xfzkqgsGlsYnEWXwTwvnnSmj_DiuJ4V3z5c3sw-lVfLj4vZxVVpuZCprCythaKCGM4bJoVklGKFRccxo0CFxS1vVNVIRVvSSSuwai0zAgMFLJuOnRWLg7f1Zqt3wQ0m3GpvnN4XfFhrE3IPPWjTMgldvkGYjiuslLKyM51qSJNHSursen9w7aZmgNbmoQTTP5A-PBndRq_9Ly04ZxiLLHhzFAT_c4KY9OCihb43I_gpasp5_hnOqczo6__QrZ_CmEeVKcYrUcm98O2BssHHGKC7fwzB-i4U-i4U-hiKjL_6t4F7-G8K2B96xLGt</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Hamdy, Sherif M</creator><creator>Abdel-Naseer, Maged</creator><creator>Shehata, Hatem S</creator><creator>Shalaby, Nevin M</creator><creator>Hassan, Amr</creator><creator>Elmazny, Alaa</creator><creator>Shaker, Ehab</creator><creator>Nada, Mona A F</creator><creator>Ahmed, Sandra M</creator><creator>Hegazy, Mohamed I</creator><creator>Mourad, Husam S</creator><creator>Abdelalim, Ahmed</creator><creator>Magdy, Rehab</creator><creator>Othman, Alshimaa S</creator><creator>Mekkawy, Doaa A</creator><creator>Kishk, Nirmeen A</creator><general>Taylor &amp; Francis Ltd</general><general>Dove</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4410-7814</orcidid><orcidid>https://orcid.org/0000-0002-3556-3749</orcidid><orcidid>https://orcid.org/0000-0001-6445-5539</orcidid><orcidid>https://orcid.org/0000-0002-4865-1457</orcidid><orcidid>https://orcid.org/0000-0003-0976-9011</orcidid><orcidid>https://orcid.org/0000-0001-5012-3998</orcidid><orcidid>https://orcid.org/0000-0002-2053-980X</orcidid><orcidid>https://orcid.org/0000-0002-8969-8825</orcidid><orcidid>https://orcid.org/0000-0002-1994-3186</orcidid><orcidid>https://orcid.org/0000-0001-7374-7074</orcidid></search><sort><creationdate>20200101</creationdate><title>Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era</title><author>Hamdy, Sherif M ; Abdel-Naseer, Maged ; Shehata, Hatem S ; Shalaby, Nevin M ; Hassan, Amr ; Elmazny, Alaa ; Shaker, Ehab ; Nada, Mona A F ; Ahmed, Sandra M ; Hegazy, Mohamed I ; Mourad, Husam S ; Abdelalim, Ahmed ; Magdy, Rehab ; Othman, Alshimaa S ; Mekkawy, Doaa A ; Kishk, Nirmeen A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-5c2679271a44b38783220907f4032e27c0d4b95b892d1f8c709dc3a70e2e08bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antibodies</topic><topic>Blood tests</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>covid19</topic><topic>Cytokines</topic><topic>Drug dosages</topic><topic>Immunoglobulins</topic><topic>Infections</topic><topic>Laboratories</topic><topic>Lymphocytes</topic><topic>neuromyelitis optica spectrum disorder</topic><topic>pandemic</topic><topic>Pandemics</topic><topic>Pathophysiology</topic><topic>Patients</topic><topic>Review</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Tumor necrosis factor-TNF</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hamdy, Sherif M</creatorcontrib><creatorcontrib>Abdel-Naseer, Maged</creatorcontrib><creatorcontrib>Shehata, Hatem S</creatorcontrib><creatorcontrib>Shalaby, Nevin M</creatorcontrib><creatorcontrib>Hassan, Amr</creatorcontrib><creatorcontrib>Elmazny, Alaa</creatorcontrib><creatorcontrib>Shaker, Ehab</creatorcontrib><creatorcontrib>Nada, Mona A F</creatorcontrib><creatorcontrib>Ahmed, Sandra M</creatorcontrib><creatorcontrib>Hegazy, Mohamed I</creatorcontrib><creatorcontrib>Mourad, Husam S</creatorcontrib><creatorcontrib>Abdelalim, Ahmed</creatorcontrib><creatorcontrib>Magdy, Rehab</creatorcontrib><creatorcontrib>Othman, Alshimaa S</creatorcontrib><creatorcontrib>Mekkawy, Doaa A</creatorcontrib><creatorcontrib>Kishk, Nirmeen A</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Therapeutics and clinical risk management</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hamdy, Sherif M</au><au>Abdel-Naseer, Maged</au><au>Shehata, Hatem S</au><au>Shalaby, Nevin M</au><au>Hassan, Amr</au><au>Elmazny, Alaa</au><au>Shaker, Ehab</au><au>Nada, Mona A F</au><au>Ahmed, Sandra M</au><au>Hegazy, Mohamed I</au><au>Mourad, Husam S</au><au>Abdelalim, Ahmed</au><au>Magdy, Rehab</au><au>Othman, Alshimaa S</au><au>Mekkawy, Doaa A</au><au>Kishk, Nirmeen A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era</atitle><jtitle>Therapeutics and clinical risk management</jtitle><addtitle>Ther Clin Risk Manag</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>16</volume><spage>759</spage><epage>767</epage><pages>759-767</pages><issn>1176-6336</issn><issn>1178-203X</issn><eissn>1178-203X</eissn><abstract>The ongoing coronavirus (COVID-19) pandemic is a global health emergency of international concern and has affected management plans of many autoimmune disorders. Immunosuppressive and immunomodulatory therapies are pivotal in the management of neuromyelitis optica spectrum disorder (NMOSD), potentially placing patients at an increased risk of contracting infections such as COVID-19. The optimal management strategy of NMOSD during the COVID-19 era remains unclear. Here, however, we examined the evidence of NMOSD disease-modifying therapies (DMTs) use during the present period and highlighted different scenarios including treatment of relapses as well as initiation and maintenance of DMTs in order to optimize care of NMOSD patients in the COVID-19 era.</abstract><cop>New Zealand</cop><pub>Taylor &amp; Francis Ltd</pub><pmid>32884277</pmid><doi>10.2147/TCRM.S261753</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-4410-7814</orcidid><orcidid>https://orcid.org/0000-0002-3556-3749</orcidid><orcidid>https://orcid.org/0000-0001-6445-5539</orcidid><orcidid>https://orcid.org/0000-0002-4865-1457</orcidid><orcidid>https://orcid.org/0000-0003-0976-9011</orcidid><orcidid>https://orcid.org/0000-0001-5012-3998</orcidid><orcidid>https://orcid.org/0000-0002-2053-980X</orcidid><orcidid>https://orcid.org/0000-0002-8969-8825</orcidid><orcidid>https://orcid.org/0000-0002-1994-3186</orcidid><orcidid>https://orcid.org/0000-0001-7374-7074</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1176-6336
ispartof Therapeutics and clinical risk management, 2020-01, Vol.16, p.759-767
issn 1176-6336
1178-203X
1178-203X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_ad38ef8327af490999c8faf9b1b17516
source PubMed Central Free; DOVE Medical Press Journals; Publicly Available Content Database; Taylor & Francis Open Access Journals; Coronavirus Research Database
subjects Antibodies
Blood tests
Coronaviruses
COVID-19
covid19
Cytokines
Drug dosages
Immunoglobulins
Infections
Laboratories
Lymphocytes
neuromyelitis optica spectrum disorder
pandemic
Pandemics
Pathophysiology
Patients
Review
Severe acute respiratory syndrome coronavirus 2
Tumor necrosis factor-TNF
Viral infections
title Management Strategies of Patients with Neuromyelitis Optica Spectrum Disorder During the COVID-19 Pandemic Era
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T22%3A43%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20Strategies%20of%20Patients%20with%20Neuromyelitis%20Optica%20Spectrum%20Disorder%20During%20the%20COVID-19%20Pandemic%20Era&rft.jtitle=Therapeutics%20and%20clinical%20risk%20management&rft.au=Hamdy,%20Sherif%20M&rft.date=2020-01-01&rft.volume=16&rft.spage=759&rft.epage=767&rft.pages=759-767&rft.issn=1176-6336&rft.eissn=1178-203X&rft_id=info:doi/10.2147/TCRM.S261753&rft_dat=%3Cproquest_doaj_%3E2434575807%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c478t-5c2679271a44b38783220907f4032e27c0d4b95b892d1f8c709dc3a70e2e08bf3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2434575807&rft_id=info:pmid/32884277&rfr_iscdi=true